5 recruiting. 5 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 5 |
| Phase 3 | 2 | Recruiting 2 |
Follow Thinness: new trials by email Literature Review of Thinness trials Research Report on Thinness
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101 Active Comparator, ASCA101 24.32mg/kg, ASCA101 32.43mg/kg - Cachexia; Cancer | Phase 2 | Recruiting | MetaFines | 135 | 2026-05-08 | 2026-06-17 |
| Visugromab in Cachexia International Trial Visugromab (CTL-002), Placebo - Cancer-associated Cachexia | Phase 2 / Phase 3 | Recruiting | CatalYm GmbH | 518 | 2026-04-16 | 2026-09-22 |
| A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue ponsegromab, placebo - Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | Pfizer | 982 | 2025-10-03 | 2026-10-14 |
| Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy TCMCB07, Placebo - Cancer Weight Loss | Phase 2 | Recruiting | Endevica Bio | 120 | 2025-04-28 | 2026-07-15 |
| Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer Olanzapine, Placebo Administration, Questionnaire Administration - Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | OHSU Knight Cancer Institute | 66 | 2024-07-17 | 2026-07-16 |
Cachexia (5) · Neoplasms (4) · Weight Loss (4) · Anorexia (3) · Colorectal Neoplasms (2) · Pancreatic Neoplasms (2) · Esophageal Neoplasms (1) · Fatigue (1) · Neoplasm Metastasis (1)
Body Weight (5) · Body Weight Changes (5) · Pathological Conditions, Signs and Symptoms (5) · Signs and Symptoms (5) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Neoplasms by Site (3) · Signs and Symptoms, Digestive (3) · Colonic Diseases (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Intestinal Diseases (2)
Olanzapine (1)
CatalYm GmbH (1) · Endevica Bio (1) · MetaFines (1) · OHSU Knight Cancer Institute (1) · Pfizer (1)
United States (4) · Bulgaria (2) · Canada (2) · France (2) · Germany (2) · Italy (2) · Poland (2) · South Korea (2) · Spain (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Brazil (1) · China (1) · Czechia (1)
Eric Roeland, M.D., FAAHPM, FASCO (1)
2025 (1), P30CA069533 (1)